Traders sold shares of Allergan PLC. (NYSE:AGN) on strength during trading hours on Friday. $108.61 million flowed into the stock on the tick-up and $132.26 million flowed out of the stock on the tick-down, for a money net flow of $23.65 million out of the stock. Of all stocks tracked, Allergan PLC. had the 30th highest net out-flow for the day. Allergan PLC. traded up $0.07 for the day and closed at $174.88
Several brokerages have recently issued reports on AGN. Morgan Stanley decreased their price objective on Allergan PLC. from $228.00 to $200.00 and set an “equal weight” rating for the company in a research note on Thursday, November 2nd. Cantor Fitzgerald decreased their price objective on Allergan PLC. to $191.00 and set a “neutral” rating for the company in a research note on Thursday, November 2nd. Wells Fargo & Company reiterated an “outperform” rating and issued a $245.00 price objective (down previously from $258.00) on shares of Allergan PLC. in a research note on Thursday, November 2nd. Royal Bank Of Canada decreased their price objective on Allergan PLC. from $250.00 to $221.00 and set an “outperform” rating for the company in a research note on Thursday, November 2nd. Finally, Zacks Investment Research upgraded Allergan PLC. from a “sell” rating to a “hold” rating in a research note on Monday, October 23rd. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating and twelve have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $246.73.
The company has a market capitalization of $57,550.00, a price-to-earnings ratio of 11.14, a PEG ratio of 1.09 and a beta of 1.12. The company has a current ratio of 1.18, a quick ratio of 1.08 and a debt-to-equity ratio of 0.40.
Allergan PLC. (NYSE:AGN) last released its earnings results on Wednesday, November 1st. The company reported $4.15 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $4.06 by $0.09. The business had revenue of $4.03 billion for the quarter, compared to analyst estimates of $4.04 billion. Allergan PLC. had a positive return on equity of 8.00% and a negative net margin of 47.27%. The company’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.32 earnings per share. equities analysts expect that Allergan PLC. will post 16.28 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, December 15th. Stockholders of record on Friday, November 17th will be issued a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.60%. The ex-dividend date is Thursday, November 16th. Allergan PLC.’s payout ratio is currently -12.39%.
Allergan PLC. declared that its board has initiated a share buyback plan on Monday, September 25th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the company to reacquire up to 2.8% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s management believes its stock is undervalued.
Several large investors have recently added to or reduced their stakes in AGN. Utah Retirement Systems boosted its stake in shares of Allergan PLC. by 0.3% in the first quarter. Utah Retirement Systems now owns 61,461 shares of the company’s stock valued at $14,684,000 after buying an additional 200 shares in the last quarter. Cornerstone Wealth Management LLC purchased a new stake in shares of Allergan PLC. in the first quarter valued at approximately $285,000. Capital Planning Advisors LLC boosted its stake in shares of Allergan PLC. by 79.3% in the first quarter. Capital Planning Advisors LLC now owns 3,674 shares of the company’s stock valued at $878,000 after buying an additional 1,625 shares in the last quarter. Golub Group LLC boosted its stake in shares of Allergan PLC. by 7.3% in the first quarter. Golub Group LLC now owns 214,207 shares of the company’s stock valued at $51,178,000 after buying an additional 14,623 shares in the last quarter. Finally, South Dakota Investment Council boosted its stake in shares of Allergan PLC. by 0.6% in the first quarter. South Dakota Investment Council now owns 201,509 shares of the company’s stock valued at $48,145,000 after buying an additional 1,240 shares in the last quarter. 81.21% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Traders Sell Shares of Allergan PLC. (AGN) on Strength (AGN)” was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://ledgergazette.com/2017/11/17/traders-sell-shares-of-allergan-plc-agn-on-strength-agn.html.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.